Statins in sepsis

Raúl Carrillo-Esper

2008, Number 2

Next >>

Cir Cir 2008; 76 (2)

Statins in sepsis

Carrillo-Esper R

Full text

How to cite this article

Language: Spanish
References: 22
Page: 99-100
PDF size: 36.68 Kb.

Text Extraction

No abstract

REFERENCES

1. Marshall JC. Sepsis: current status, future prospects. Curr Opin Crit Care 2004;10:250-264.
2. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001;29: 1303-1310.
3. Terblanche M, Almong Y, Rosenson RS, Smith TS, Hackam DG. Statins: panacea for sepsis? Lancet Infect Dis 2006;6:242-248.
4. Dellinger RP, Carlet JM, Masur H. Surviving sepsis campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2004;32: 858-873.
5. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscl Thromb Vasc Biol 2001;21: 1712-1719.
6. Rosenson RS. Statin therapy: New therapy for cardiac microvascular dysfunction. Eur Heart J 2003;24:1993-1994.
7. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990;343:425-430.
8. Zingarelli B. Nuclear factor-kb. Crit Care Med 2005;33:414-416.
9. Terblanche M, Almong Y, Rosenson RS, Smith TS, Hackman DG. Statins and sepsis: multiple modifications at multiple levels. Lancet Infect Dis 2007;7:358-368.
10. Mach F. Statins as immunomodulators. Transplant Immunol 2002;9:197-200.
Wang HR, Li JJ, Huang CX, Jiang H. Fluvastatin inhibits the expression of tumor necrosis factor-alpha and activation of nuclear factor-kB in human endothelial cells stimulated by C-reactive protein. Clin Chim Acta 2005;353:53-60.
12. Kwak B, Mullhaupt F, Myit S, Mach F. Statins as a newly recognized type of immunomodulator. Nat Med 2000;6:1399-1402.
13. Merx MW, Liehn EA, Janssens U. HMG-CoA reductase inhibitor simvastatin profoundly improves survival in a murine model of sepsis. Circulation 2004;109:2560-2565.
14. Ando H, Takamura T, Ota T, Nagai Y, Kobayashi K. Cerivastatin improves survival of mice with lipopolysacharide-induced sepsis. J Pharmacol Exp Ther 2000;294:1043-1046.
15. Jerwood S, Cohen J. Unexpected antimicrobial effect of statins. J Antimicrob Chemoter 2007;60:1885-1886.
16. Schmidth H, Hennen R, Keller A. Association of statin therapy and increased survival in patients with multiple organ dysfunction syndrome. Intensive Care Med 2006;32:1248-1251.
17. Thomsen RW, Hundborg HH, Johnsen SP. Statin use and mortality within 180 days after bacteremia: a population-based cohort study. Crit Care Med 2006;34:1080-1086.
Almong Y, Novack V, Eisinger M, Porath A, Novack L, Gilutz H. The effect of statin therapy on infection-related mortality in patients with atherosclerotic diseases. Crit Care Med 2007;35:372-378.
19. Hackam DG, Mamdani M, Li P, Redelmeier DA. Statins and sepsis in patients with cardiovascular disease: a population-based cohort analysis. Lancet 2006;367:413-418.
20. Majumdar S, McAlister FA, Eurich DT, Padwal RS, Marrie TJ. Statins and outcomes in patients admitted to hospital with community acquired pneumonia: population based prospective cohort study. BMJ 2006;333:999-1003.
21. Fedson DS. Pandemic influenza: a potential role for statins in treatment and prophylaxis. Clin Infect Dis 2006;43:199-205.
22. Natanson C, Esposito CJ, Banks SM. The sirens’ songs of confirmatory sepsis trials: selection bias and sampling error. Crit Care Med 1998;26:1927-1931.